Trump Administration Cuts CDC’s Key Role in Global Program to Stop HIV

Why It Matters

Removing CDC’s technical support threatens the effectiveness of the world’s largest HIV/AIDS program and could erode U.S. influence in global health security. The change also raises fiscal‑accountability concerns for Congress and taxpayers.

Key Takeaways

• CDC's role in PEPFAR ends in most countries after May 5 guidance
• Only 31 of 46 recipient nations have signed new MOUs
• Congress allocated $4.5 billion this fiscal year to PEPFAR
• Countries receiving >$125 million must pay CDC fees for services
• Experts warn program cut could weaken US health security worldwide

Pulse Analysis

PEPFAR, launched in 2003, has been the cornerstone of U.S. effort to combat HIV/AIDS abroad, delivering antiretroviral therapy and prevention services to an estimated 26 million people. Funded at $4.5 billion this year, the program’s success has hinged on the CDC’s technical expertise, which integrated surveillance, laboratory quality, and community outreach across 46 low‑income nations. By embedding CDC staff within ministries of health, the agency helped build resilient health systems that also responded to emerging threats like Marburg and mpox.

The Trump administration’s new “America First Global Health Strategy” reconfigures that model, shifting most PEPFAR dollars to bilateral agreements that require recipient governments to sign memoranda of understanding. Under the guidance, CDC assistance becomes a fee‑for‑service offering, with nations receiving over $125 million in aid forced to purchase surveillance and lab support. To date, only 31 countries have signed MOUs, and several major recipients are locked in negotiations over resource‑access conditions. Critics argue the fee structure undermines the collaborative “secret sauce” that made PEPFAR effective and risks creating gaps in HIV treatment continuity.

If CDC’s on‑the‑ground capacity erodes, the broader implications extend beyond HIV. The agency’s presence has been pivotal for rapid response to outbreaks and for maintaining data pipelines that inform U.S. public‑health preparedness. Congressional oversight, which traditionally safeguards the $115 billion invested in global health, may be sidelined, raising concerns about financial mismanagement and reduced accountability. Stakeholders warn that a hasty transition could reverse decades of progress, jeopardizing both global disease control and America’s own health security.